Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study
Authors:
Open Access
- 13 July 2022
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 365, 34-40
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Leukotriene B4 Levels in Human Atherosclerotic Plaques and Abdominal Aortic AneurysmsPLOS ONE, 2014
- Genetic contribution of the leukotriene pathway to coronary artery diseaseHuman Genetics, 2011
- Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary SyndromeCirculation: Cardiovascular Imaging, 2010
- LeukotrienesNew England Journal of Medicine, 2007
- Association Between A Leukotriene C 4 Synthase Gene Promoter Polymorphism and Coronary Artery Calcium in Young WomenArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Expression of 5-lipoxygenase and leukotriene A 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instabilityProceedings of the National Academy of Sciences, 2006
- Association Between 5-Lipoxygenase Expression and Plaque Instability in HumansArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial InfarctionJAMA, 2005
- Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and AtherosclerosisNew England Journal of Medicine, 2004
- Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesisProceedings of the National Academy of Sciences, 2003